TY - JOUR T1 - Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients JF - Hepatology Y1 - 2009 A1 - George, S.L. A1 - Bacon, B.R. A1 - Brunt, E.M. A1 - Mihindukulasuriya, K.L. A1 - Hoffmann, J. A1 - A M Di Bisceglie KW - Adult KW - Aged KW - Alanine KW - Alanine Transaminase KW - Antiviral Agents KW - Aspartate Aminotransferases KW - Biopsy KW - blood KW - Carcinoma KW - Disease KW - drug effects KW - drug therapy KW - Drug Therapy,Combination KW - Female KW - Fibrosis KW - Follow-Up Studies KW - genetics KW - Genotype KW - HCV KW - Hepacivirus KW - hepatitis KW - Hepatitis C KW - Humans KW - Inflammation KW - interferon KW - Interferon Alfa-2b KW - Interferon-alpha KW - Internal Medicine KW - Liver KW - Male KW - Medicine KW - Middle Aged KW - pathology KW - Patients KW - peginterferon KW - peginterferon alfa-2b KW - physiology KW - Polyethylene Glycols KW - Proteins KW - Recombinant Proteins KW - Research KW - Research Support KW - Ribavirin KW - Risk KW - Serum KW - sustained virologic response KW - SVR KW - therapeutic use KW - therapy KW - treatment KW - Treatment Outcome KW - virology VL - 49 SP - 729-738 IS - 3 N1 - PMC2731713 ER -